Arthritis & Rheumatism - Confex

1265 Pages·2011·17.9 MB·English

V
O
L
U
M
E
6
3
,
N
U
M
B
E
R
10
(S
U
P
P
L
E
M
E
N
T
)
(P
P
.
S
1–
S
12
5
6
)
A
r
t
h
r
i
t
i
s
&
R
h
e
u
m
a
t
i
s
m
/A
b
s
tra
c
ts
O
C
T
O
B
E
R
2
0
1
1
AN OFFICIAL JOURNAL OF THE AMERICAN COLLEGE OF RHEUMATOLOGY
Arthritis & Rheumatism
VOLUME 63, NUMBER 10 (SUPPLEMENT) OCTOBER 2011
ABSTRACT SUPPLEMENT
2011 ANNUAL SCIENTIFIC MEETING
November 4–9, 2011
Chicago, Illinois
AMERICAN COLLEGE OF RHEUMATOLOGY
ABSTRACT SUPPLEMENT
American College of Rheumatology
75th Annual Scientific Meeting
Association of Rheumatology Health Professionals
46th Annual Scientific Meeting
November 4-9, 2011 Chicago, IL
Copyright © 2011 by the American College of Rheumatology, Atlanta, GA
The printing of the 2011 ACR Annual Scientific Meeting Abstract Supplement was supported by Savient Krystexxa, Inc.
ACR/ARHP 2011 Annual • A specific pediatric rheumatology track plus content
integrated throughout the program designed to provide a
Scientific Meeting Overal Needs high-level educational program to pediatric rheumatologists;
and relevant updates to adult rheumatologists;
Assessment/Practice Gaps
• Formal presentations of new practice guidelines provided
The American College of Rheumatology and the Association of to alert the membership and explain, in an open forum, the
Rheumatology Health Professionals are committed to providing data supporting the guidelines and propose approaches for
comprehensive education to improve the knowledge and implementation;
performance of physicians, health professionals and scientists.
• Over 40 workshops designed to provide hands-on skills
Through evidence-based educational programs, the organization
training.
strives to enhance practice performance and improve the quality
For additional details, refer to the session level learning objectives
of care in those with or at risk for arthritis, rheumatic and
at www.rheumatology.org/annual.
musculoskeletal diseases. The 2011 annual meeting program
has been developed independent of commercial influence. The
following groups were involved in the planning process: the ACR About ACR/ARHP Education
Committee on Education; the ACR Annual Meeting Planning
Committee; the ARHP Education Committee and the ARHP Annual The American College of Rheumatology and the Association of
Meeting Program Planning Committee. Rheumatology Health Professionals, a division of the ACR, are
organizations of physicians, health professionals and scientists
The program is the result of a planning process that identified
serving members through programs, including education and
educational needs to change or enhance the knowledge,
research. Through these programs, the ACR and the ARHP
competence or performance of rheumatology professionals. The
foster excellence in the care of people with rheumatic and
program’s content was derived from both needs assessment and
musculoskeletal diseases. The 2011 ACR/ARHP Annual Scientific
practice gap analysis based on professional activities, practice
Meeting programs have been independently planned by the
setting, ABIM recertification requirements and physician attributes.
ACR Committee on Education, the ACR Annual Meeting Planning
Committee, the ARHP Annual Meeting Program Committee, and
PROGRAM HIGHLIGHTS
the ARHP Clinical Focus Course Task Force.
• Educational tracks to help attendees identify content targeted
This program is sponsored by the American College of
to them. Tracks include: business of rheumatology, clinical,
Rheumatology for educational purposes only. The material
clinical and research, clinical practice, educators, fellow-in-
presented is not intended to represent the only or the best
training, pediatrics, pediatrics and clinical, and research;
methods appropriate for the medical conditions being discussed,
• Latest science and best-practices presented through peer-
but rather are intended to present the opinions of the authors/
reviewed and selected clinical and scientific abstracts, and
presenters, which may be helpful to other healthcare professionals.
invited speakers providing clinical, evidence-based and quality
Attendees participating in this medical education program do so
focused content;
with the full knowledge that they waive any claim they may have
• Diverse formats of education delivery, including: didactic against the ACR for reliance on any information presented during
lectures, debates, and interactive sessions, such as poster these educational activities. The ACR does not guarantee, warrant
tours, Meet the Professors and Workshop sessions; or endorse any commercial products or services.
• A larger forum for discussion of practical management issues
PROGRAM OBJECTIVES
such as the Curbside Consults – Ask the Professors session and
At the conclusion of the 2011 ACR/ARHP annual meeting,
Medical Aspects lectures;
participants should be able to:
• Extensive learning opportunities in the basic science of
• identify recent developments in the diagnosis and
rheumatology, an area of the program developed by a
management of patients with rheumatic diseases
subcommittee of US and internationally prominent basic
scientists. Offerings include: Basic Science Symposia, State- • outline new technologies for the treatment of rheumatologic
of-the-Art Lectures, a series of Immunology Updates for the problems
Clinicians, and a Basic Science pre-meeting course;
• describe potential challenges in the delivery of care to patients
• Clinical management sessions, including the Thieves’ Market, with rheumatic diseases and to specify possible solutions
Curbside Consults – Ask the Professors, The Great Debate and
• utilize new research data to improve the quality of care of
the ACR Knowledge Bowl;
patients with rheumatic diseases
• summarize recent rheumatology research findings
Certificates of CME Credit or None: Nothing to disclose
1. Stock, stock options or bond holdings in a for-profit
Participation
corporation or self-directed pension plan
2. Research grants
Accreditation Statement: The American College of Rheumatology
is accredited by the Accreditation Council for Continuing Medical 3. Employment (full or part-time)
Education (ACCME) to provide continuing medical education for 4. Ownership or partnership
physicians. 5. Consulting fees or other remuneration (payment)
Statement of Designation: The ACR designates this live educational 6. Non-remunerative positions of influence such as officer,
activity for a maximum of 47.25 AMA PRA Category 1 credits™. board member, trustee or public spokesperson
Physicians should claim only the credit commensurate with the 7. Receipt of royalties
extent of their participation in the activity.
8. Speakers’ bureau
International Physicians: International physicians who register as 9. Other
part of a group and require AMA PRA Category 1 Credit(s)™, must
Speakers, moderators and abstract authors submitted their
provide the following information to your tour leader: full name,
disclosure online prior to publication. Disclosures for invited
mailing address, telephone and fax numbers, and e-mail address.
speakers are listed in the indices by presenters’ last name.
The information will be used to verify your meeting attendance.
Abstract author disclosures are published online and in a
The American Medical Association has an agreement of mutual
supplement to the October issue of Arthritis & Rheumatism.
recognition of continuing medical education credit with the
Disclosures for the Late-Breaking abstracts are published online
European Union of Medical Specialties. International physicians
and in the December issue of Arthritis & Rheumatism. Any
interested in converting AMA PRA Category 1 Credit ™ to EACCME
individual who refuses to disclose relevant financial relationships
credit should contact the UEMS.
will be disqualified from being a planning committee member, a
Health Professionals: Participants may claim hours to receive a presenter, an author of a CME activity, and cannot have control of,
Certificate of Participation for an activity designated for AMA PRA or responsibility for, the development, management, presentation
Category 1 Credit(s)™. For non-CME sessions, attendees may also or evaluation of the CME activity.
request a certificate of participation.
ACr DISCloSure PolICy
Meeting Evaluations, CME Credit/
It is the policy of the American College of Rheumatology to ensure
Certificates of Participation that its CME activities are independent and free of commercial
bias.
Computers are available for you to complete your CME/Certificate
To ensure content objectivity and balance, and guarantee that
of Participation application and meeting evaluation form online
the content presented is in the best interest of its learners and
during the meeting. In addition, you can complete the evaluation
the public, the ACR requires that everyone in a position to control
and print your certificate after you return home.
content disclose all relevant financial relationships with any
If you are an international physician and require a Certificate of commercial interest if the relationship is financial and occurred
Attendance, this is enclosed in your meeting bag. If your country within the past 12 months. If there are relationships that create a
recognizes AMA PRA Category 1 Credit(s)™ in accordance with conflict of interest, these must be resolved in accordance with the
AMA PRA requirements, please complete a meeting evaluation and ACR’s CME Resolution of Conflict policy prior to the participation of
CME application. the individual in the development or presentation of CME content.
Your evaluation of the meeting is very important. The ACR/ ARHP
CoPyrIGHt mAterIAlS PolICy
annual meeting planning committees use feedback from attendees
The annual meeting is a private event. Programs presented at
to assist in the development of future educational activities;
the meeting are for the education of attendees and purchasers
therefore, we encourage you to complete your evaluation and
of recorded presentations as authorized by the American College
CME/Certificate application online.
of Rheumatology. The information and materials displayed
and presented during this meeting are the property of the
ConflICt of IntereSt/DISCloSure StAtementS
(See index for Authors Disclosures) ACR and the presenter and cannot be photographed, copied,
As an educational provider accredited by the Accreditation Council photocopied, transformed to electronic format, reproduced, or
for Continuing Medical Education (ACCME), the American College distributed without written permission of the American College of
of Rheumatology must ensure balance, independence, objectivity Rheumatology and the presenter. Any use of the program content
and scientific rigor in all its educational activities. Therefore, all for commercial purposes, which includes, but is not limited to
speakers and moderators participating in an ACR-sponsored activity oral presentations, audiovisual materials used by speakers, and
are required to disclose to the planning committee and audience program handouts without the written consent of the ACR is
any financial or other relationships including, but not limited to: prohibited. This policy applies before, during and after the meeting.
The ACR will enforce its intellectual property rights and penalize
those who infringe upon it.
The names, insignias, logos and acronyms of the ACR, the ARHP
and the REF are proprietary marks. Use of the names in any
fashion, by any entity, for any purpose, is prohibited without
the express written permission of the American College of
Rheumatology.
emBArGo PolICy
Accepted abstracts are made available to the public online in
advance of the meeting and are published in a special supplement
of Arthritis & Rheumatism. Information contained in those
abstracts may not be released until the abstracts appear online.
Academic institutions, private organizations and companies with
products whose value may be influenced by information contained
in an abstract may issue a press release to coincide with the
availability of an ACR abstract online.
However, the ACR continues to require that information that goes
beyond that contained in the abstract, e.g., discussion of the
abstract done as part a scientific presentation or presentation of
additional new information that will be available at the time of the
meeting, is under embargo until 5:00 pm Eastern Time on Saturday,
November 5. Violation of this policy may result in the abstract
being withdrawn from the meeting and other measures deemed
appropriate.
Authors are responsible for notifying financial and other sponsors
about this policy.
table of Contents
SunDAy, novemBer 6, 2011 2:30 - 4:00 pm
ARHP Concurrent Abstract Session
9:00 am - 6:00 pm
ARHP Epidemiology and Public Health I
ACR Poster Session A
(Abstracts #795-800)............................S313
Poster presenters will be available from 9:00 – 11:00 am.
(Abstracts #1-717)................................S1 4:30 - 6:00 pm
ACR Concurrent Abstract Sessions
11:00 am - 12:30 pm
Epidemiology and Health Services Research V: Drugs
ACR Plenary Session I
(Abstracts #801-806)............................S316
Discovery 2011
(Abstracts #718-722) ...........................S279 Imaging of Rheumatic Disease I: Ultrasonography and Dual-
emission X-ray Absorptiometry (DEXA)
2:30 - 4:00 pm (Abstracts #807-812)............................S318
ACR Concurrent Abstract Sessions
Innate Immunity and Rheumatic Disease
Antiphospholipid Syndrome (Abstracts #814-818)............................S320
(Abstracts #723-728)............................S281
Muscle Biology, Myositis and Myopathies: Insights into the
Cell-cell Interactions and Adhesion Pathogenesis of Myositis
(Abstracts #729-734)............................S284 (Abstracts #819-824)............................S322
Fibromyalgia and Soft Tissue Disorders I Osteoarthritis - Clinical Aspects I
(Abstracts #735-740)............................S286 (Abstracts #825-830)............................S324
Orthopedics and Low Back Pain Rheumatoid Arthritis - Animal Models I
(Abstracts #741-746)............................S288 (Abstracts #831-836)............................S327
Pediatric Rheumatology - Clinical and Therapeutic Aspects: Rheumatoid Arthritis Treatment - Small Molecules, Biologics,
Clinical Characteristics Therapy: Biomarkers
(Abstracts #747-752)............................S291 (Abstracts #837-842)............................S330
Quality Measures and Innovations in Practice Management Systemic Sclerosis Fibrosing Syndromes and Raynaud’s -
and Care Delivery I Clinical Aspects and Therapeutics I
(Abstracts #753-758)............................S294 (Abstracts #843-848)............................S332
Rheumatoid Arthritis Clinical Aspects: Cardiovascular Disease T-cell Biology and Targets in Autoimmune Disease:
(Abstracts #759-764)............................S297 Lymphocyte Biology and Targets in Autoimmune Disease
Rheumatoid Arthritis - Human Etiology and Pathogenesis I: (Abstracts #849-854)............................S334
Pathogenesis of the Earliest Stages of Rheumatoid Arthritis Vasculitis II
(Abstracts #765-770)............................S300 (Abstracts #855-860)............................S336
Sjögren’s Syndrome
4:30 - 6:00 pm
(Abstracts #771-776)............................S302
ACR/ARHP Combined Abstract Session
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects
ACR/ARHP Combined Pediatrics Abstract Session
and Treatment I
(Abstracts #861-866)............................S338
(Abstracts #777-782)............................S305
Systemic Lupus Erythematosus - Clinical Aspects: Cardiac 4:30 - 6:00 pm
Disease/Organ Damage ARHP Concurrent Abstract Session
(Abstracts #783-788)............................S307 ARHP Clinical Practice/Patient Care I
Vasculitis I (Abstracts #867-872)............................S341
(Abstracts #789-794)............................S310
table of Contents
monDAy, novemBer 7, 2011 Systemic Lupus Erythematosus - Human Etiology and
Pathogenesis I
9:00 am - 6:00 pm
(Abstracts #1659-1664)..........................S649
ACR/ARHP Poster Session B*
(Abstracts in this session are not in sequential order. Abstracts 2:30 - 4:00 pm
#873 and #874 have been re-numbered as #2486A and #2486B ARHP Concurrent Abstract Session
and can be found on page 10). ARHP Education and Community Programs
Poster presenters will be available from 9:00 – 11:00 am. (Abstracts #1665-1670)..........................S651
(Abstracts #875-1586) ..........................S344
4:30 - 6:00 pm
11:00 am - 12:30 pm ACR Concurrent Abstract Sessions
ACR Plenary Session II Cytokines, Mediators, and Gene Regulation I
Discovery 2011 (Abstracts #1671-1676)..........................S653
(Abstracts #1587-1592)..........................S619 Genetics, Genomics, and Proteomics
2:30 - 4:00 pm (Abstracts #1677-1682)..........................S656
ACR Concurrent Abstract Sessions Pediatric Rheumatology-Pathogenesis
Education: Medical Education (Abstracts #1683-1688)..........................S658
(Abstracts #1593-1598) .........................S622 Rheumatoid Arthritis Clinical Aspects: Clinical Features
Epidemiology and Health Services Research I: Gout (Abstracts #1689-1694)..........................S661
(Abstracts #1599-1604)..........................S624 Rheumatoid Arthritis Treatment - Small Molecules, Biologics,
Therapy: Existing Disease-modifying Antirheumatic Drugs
Fibromyalgia and Soft Tissue Disorders II
(DMARDs) - Tight Control, Induction and Drug Withdrawal
(Abstracts #1605-1610)..........................S627
Trials
Imaging of Rheumatic Disease II: X-ray, Computed
(Abstracts #1695-1700)..........................S663
Tomography (CT) and Magnetic Resonance Imaging (MRI)
Spondylarthropathies and Psoriatic Arthritis – Pathogenesis,
(Abstracts #1611-1616)..........................S629
Etiology
Metabolic and Crystal Arthropathies I: Concurrent Session on
(Abstracts #1701-1706)..........................S666
Pathogenesis of Gout, a Potential Novel Therapy, and Validity
Systemic Lupus Erythematosus - Clinical Aspects: General
of Dual Energy Computed Tomography
(Abstracts #1617-1622)..........................S632 (Abstracts #1707-1712)..........................S669
Systemic Sclerosis Fibrosing Syndromes and Raynaud’s -
Osteoarthritis - Clinical Aspects II
Clinical Aspects and Therapeutics II
(Abstracts #1623-1628)..........................S634
(Abstracts #1713-1718)..........................S672
Osteoporosis and Metabolic Bone Disease: Clinical Aspects
and Pathogenesis 4:30 - 6:00 pm
(Abstracts #1629-1634)..........................S637 ACR/ARHP Combined Abstract Session
Rheumatoid Arthritis - Animal Models II ACR/ARHP Combined Rehabilitation Abstract Session
(Abstracts #1635-1640)..........................S639 (Abstracts #1719-1724)..........................S675
Rheumatoid Arthritis Treatment - Small Molecules, Biologics,
4:30 - 6:00 pm
Therapy: Existing Biologics
ACR REF Special Session
(Abstracts #1641-1646)..........................S641
ACR REF Marshall J. Schiff, MD, Memorial Lectureship:
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects
Multicenter Orthopaedic Outcomes Network - A Prospective
and Treatment II
Longitudinal Cohort of Anterior Cruciate Ligament (ACL)
(Abstracts #1647-1652)..........................S644 Reconstruction Outcomes
Systemic Lupus Erythematosus - Clinical Aspects: Renal (Abstracts #1725-1726)..........................S677
(Abstracts #1653-1658)..........................S646
*Abstracts in this session are not in sequential order.
table of Contents
4:30 - 6:00 pm Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects
ARHP Concurrent Abstract Session and Treatment
ARHP Health Services Research (Abstracts #2486A-2486F) .......................S970
(Abstracts #1727-1732)..........................S678 2:30 - 4:00* pm
ACR REF Special Session*
tueSDAy, novemBer 8, 2011
(Abstracts in this session are not in sequential order. Abstracts
9:00 am - 6:00 pm #2487-2492 can be found directly below this session).
ACR Poster Session C REF Edmond L. Dubois, MD, Memorial Lectureship:
Interfering with Vascular Health: How Innate Immunity
Poster presenters will be available from 9:00 – 11:00 am.
Promotes Premature Organ Damage in Systemic Lupus
(Abstracts #1733-2426)..........................S681
Erythematosus
11:00 am - 12:30 pm (Abstracts #2547-2552) ..........................S997
ACR Plenary Session III
2:30 - 4:00 pm
Discovery 2011
ARHP Concurrent Abstract Session
(Abstracts #2427-2432)..........................S944
ARHP Psychology/Social Sciences
2:30 - 4:00 pm (Abstracts #2487-2492)..........................S973
ACR Concurrent Abstract Sessions
4:30 - 6:00 pm
Biology and Pathology of Bone and Joint: Molecular Targets
ACR Concurrent Abstract Sessions
for an Effective Therapy
B-cell Biology and Targets in Autoimmune Disease
(Abstracts #2433-2438)..........................S947
(Abstracts #2493-2498)..........................S975
Epidemiology and Health Services Research VI: Lupus/
Cytokines, Mediators, and Gene Regulation II
Vasculitis
(Abstracts #2439-2444)..........................S949 (Abstracts #2499-2504)..........................S977
Epidemiology and Health Services Research II: Osteoarthritis
Miscellaneous Rheumatic and Inflammatory Diseases
(Abstracts #2445-2450)..........................S952 (Abstracts #2505-2510)..........................S980
Rheumatoid Arthritis Clinical Aspects: Predictors of Outcome
Pediatric Rheumatology - Clinical and Therapeutic Aspects:
Predictors and Outcomes (Abstracts #2511-2516)..........................S982
(Abstracts #2451-2456)..........................S954 Rheumatoid Arthritis - Human Etiology and Pathogenesis II:
Pathogenesis of Rheumatoid Arthritis - What’s New?
Rheumatoid Arthritis Clinical Aspects: Diagnostic and
Remission Criteria (Abstracts #2517-2522)..........................S985
(Abstracts #2457-2462)..........................S957 Rheumatoid Arthritis Treatment - Small Molecules, Biologics,
Therapy: Further Insights into Efficacy and Safety of Tumor
Rheumatoid Arthritis Treatment - Small Molecules, Biologics,
Necrosis Factor (TNF)-Inhibitors
Therapy: Existing Disease-modifying Antirheumatic Drugs
(DMARDs) and Corticosteroids (Abstracts #2523-2528)..........................S987
(Abstracts #2463-2468)..........................S960 Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects
and Treatment III
Systemic Lupus Erythematosus - Clinical Aspects: New
Therapies (Abstracts #2529-2534)..........................S990
(Abstracts #2469-2474)..........................S962 Systemic Sclerosis Fibrosing Syndromes and Raynaud’s -
Pathogenesis, Animal Models and Genetics I
Systemic Lupus Erythematosus - Human Etiology and
Pathogenesis II: Genetics (Abstracts #2535-2540)..........................S992
(Abstracts #2475-2480)..........................S965
Systemic Sclerosis Fibrosing Syndromes and Raynaud’s -
Clinical Aspects and Therapeutics III
(Abstracts #2481-2486)..........................S968
*Abstracts in this session are not in sequential order.
table of Contents
4:30 - 6:00 pm 9:00 - 10:30 am
ARHP Concurrent Abstract Session* ARHP Concurrent Abstract Session
(Abstracts in this session are not in sequential order. Abstracts ARHP Rehabilitation Science
#2547-2552 can be found on page 10). (Abstracts #2609-2614).........................S1025
ARHP Research Methodology
11:00 am - 12:30 pm
(Abstracts #2553-2558)..........................S999
ACR Concurrent Abstract Sessions
Infection-Related Rheumatic Disease
WeDneSDAy, novemBer 9, 2011
(Abstracts #2615-2620).........................S1027
7:30 - 8:30 am Pediatric Rheumatology - Clinical and Therapeutic Aspects:
ARHP Concurrent Abstract Session Treatment
ARHP Clinical Practice/Patient Care II (Abstracts #2621-2626).........................S1029
(Abstracts #2561-2566).........................S1004 Rheumatoid Arthritis Treatment - Small Molecules, Biologics,
Therapy: Novel Compounds II
9:00 - 10:30 am
(Abstracts #2627-2632).........................S1032
ACR Concurrent Abstract Sessions
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects
Cytokines, Mediators, and Gene Regulation III
and Treatment IV
(Abstracts #2567-2572).........................S1007
(Abstracts #2633-2638).........................S1035
Epidemiology and Health Services Research III: Rheumatoid
Arthritis 11:00 am - 12:30 pm
(Abstracts #2573-2578).........................S1009 ARHP Concurrent Abstract Session
Metabolic and Crystal Arthropathies II: Anti-Gout Medications ARHP Epidemiology and Public Health II
– Dosing, Adverse Effects, and Economic Burden (Abstracts #2639-2644).........................S1038
(Abstracts #2579-2584).........................S1012
ACR/ARHP Abstract
Rheumatoid Arthritis Clinical Aspects: Risk of Cardiovascular Author Disclosures .... ..............................................S1041
Disease
(Abstracts #2585-2590).........................S1014
Rheumatoid Arthritis Treatment - Small Molecules, Biologics,
Therapy: Novel Compounds I
(Abstracts #2591-2596).........................S1017
Systemic Lupus Erythematosus - Clinical Aspects:
Translational Studies
(Abstracts #2597-2602).........................S1020
Systemic Sclerosis Fibrosing Syndromes and Raynaud’s -
Pathogenesis, Animal Models and Genetics II
(Abstracts #2603-2608).........................S1022
9:00 - 10:30 am
ARHP Concurrent Abstract Session*
(Abstracts in this session are not in sequential order. Abstracts
#2609-2614 can be found directly below this session).
ARHP Clinical Practice/Patient Care III
(Abstracts #2559A-2560) .......................S1003
*Abstracts in this session are not in sequential order.